Cardiff Oncology, Inc.

NasdaqCM:CRDF Voorraadrapport

Marktkapitalisatie: US$86.8m

Cardiff Oncology Beheer

Beheer criteriumcontroles 2/4

De CEO Cardiff Oncology is Mani Mohindru, benoemd in Jan2026, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.036% van de aandelen van het bedrijf, ter waarde $ 31.37K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.5 jaar en 11.9 jaar.

Belangrijke informatie

Mani Mohindru

Algemeen directeur

US$183.7k

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOless than a year
Eigendom CEO0.04%
Management gemiddelde ambtstermijnless than a year
Gemiddelde ambtstermijn bestuur11.9yrs

Recente managementupdates

Recent updates

Seeking Alpha • Jun 27

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Summary Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans. Short interest is high, increasing volatility and squeeze potential if trial data is strong, but also signaling caution from sophisticated investors. CRDF's cash runway is sufficient for the near-term catalyst; I hold call options expecting momentum to return, as the July 29th readout date approaches. Read the full article on Seeking Alpha
Analyseartikel • May 21

Is Cardiff Oncology (NASDAQ:CRDF) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 18

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II results indicate superior efficacy in first-line treatment, supporting Cardiff's financial stability and long-term investment potential. The competitive landscape includes therapies like LUMAKRAS and KRAZATI, but Onvansertib's mutation-agnostic approach offers a unique advantage. Despite high risks, Cardiff's cash runway and positive clinical data justify a "Strong Buy" rating for high-risk tolerant long-term investors. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Summary Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when combined with standard chemotherapy and bevacizumab, but patient numbers remain low, necessitating further validation. Financially, CRDF's equity raise extends their cash runway, supporting the continued development and reducing immediate financial risk. Despite uncertainties, I maintain a Buy rating, anticipating onvansertib's potential to significantly impact first-line RAS-mutant mCRC therapy. Read the full article on Seeking Alpha
Seeking Alpha • Nov 07

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

Summary Cardiff Oncology's main focus is onvansertib, a PLK1 inhibitor, showing promise in metastatic colorectal cancer, especially in bevacizumab-naive patients. CRDF-004 phase 2 trial's results are crucial for Cardiff's future, with data expected within two months, potentially informing a pivotal phase 3 trial. Financially, Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder dilution. While optimistic about onvansertib's potential, I caution investors due to the high-risk nature and uncertain outcomes of the upcoming trial results. Read the full article on Seeking Alpha
Analyseartikel • Oct 09

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 04

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer. Cardiff's strong financial position, low cash burn, and favorable analyst ratings make it a compelling buy, with substantial growth potential in the mCRC market and beyond. Read the full article on Seeking Alpha
Analyseartikel • Jun 19

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Mar 09

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Summary Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy. Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial. Read the full article on Seeking Alpha
Analyseartikel • Mar 03

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Nov 16

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Aug 01

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

CEO

Mani Mohindru (54 yo)

less than a year
Tenure
US$183,670
Compensatie

Dr. Mani Mohindru, Ph D., is Co-Founder, President and Director of Roshon Therapeutics. She had been Interim Chief Executive Officer at Cardiff Oncology, Inc. since January 27, 2026 until April 09, 2026 an...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Mani Mohindru
Presidentless than a yearUS$183.67k0.036%
$ 31.4k
Roger Sidhu
Chief Medical Officer1.1yrsUS$2.47m0%
$ 0
Josh Muntner
Chief Financial Officerless than a yeargeen gegevens0.00073%
$ 633.9
Ajay Aggarwal
Chief Operating Officerless than a yeargeen gegevensgeen gegevens
Brigitte Lindsay
Chief Accounting Officerless than a yeargeen gegevens0.040%
$ 34.8k
Tod Smeal
Chief Scientific Officer4.5yrsUS$4.17mgeen gegevens
Elizabeth Anderson
VP of Finance & Administration11yrsgeen gegevensgeen gegevens
0.5yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van CRDF wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.5 jaar), wat duidt op een nieuw team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Mani Mohindru
President5.1yrsUS$183.67k0.036%
$ 31.4k
Charles Cantor
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Gary Pace
Independent Director6.3yrsUS$184.17k2.02%
$ 1.8m
K. Hirth
Member of Scientific Advisory Board11.9yrsgeen gegevensgeen gegevens
Paul Billings
Member of Scientific Advisory Board13.7yrsUS$35.85kgeen gegevens
Rodney Markin
Independent Chairman of the Board12.4yrsUS$225.67k0.045%
$ 39.4k
Carlo Croce
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Riccardo Dalla-Favera
Member of Scientific Advisory Board16.3yrsgeen gegevensgeen gegevens
Lale White
Independent Director6.3yrsUS$189.17k0.17%
$ 144.5k
Alberto Bardelli
Member of Scientific Advisory Board11.8yrsgeen gegevensgeen gegevens
Renee Tannenbaum
Independent Director5.1yrsUS$181.67k0.029%
$ 25.4k
Brunangelo Falini
Member of Scientific Advisory Board16.3yrsgeen gegevensgeen gegevens
11.9yrs
Gemiddelde duur
74yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CRDF zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.9 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/07/04 04:11
Aandelenkoers aan het einde van de dag2026/07/02 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Cardiff Oncology, Inc. wordt gevolgd door 14 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Paul KnightBrean Capital Historical (Janney Montgomery)
Bryan BrokmeierCantor Fitzgerald & Co.
Gum-Ming LoweCraig-Hallum Capital Group LLC